Online GLP-1 providers: the complete map of the US market
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
The online GLP-1 market has three lanes, and confusing them is how people overpay. Lane one — compounded telehealth (32 programs indexed): pharmacy-made tirzepatide and semaglutide, cash-pay, $215–$597/mo verified, legally confined since 2025 to patient-specific 503A prescriptions with documented need. Lane two — brand telehealth (9 programs): platforms like Ro, Hims & Hers↗, and WeightWatchers Clinic↗ that prescribe FDA-approved Zepbound, Wegovy, Ozempic, and Mounjaro, where the platform fee buys prescribing, monitoring, and often insurance work. Lane three — manufacturer direct: LillyDirect↗ (Zepbound vials $299–$449) and NovoCare↗ (Wegovy $349; oral pill from $149), the price floors for approved product.
Below: the cheapest verified programs from lane one, plus the lane-two and lane-three reference points, so the whole market sits on one page. Every program in every lane has a full record at /providers/.
RANK01
NexLife
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$215/MO ALL-IN
RANK02
Yucca Health
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$258/MO ALL-IN
RANK04
Mochi Health
Dose-flat — the maintenance price equals the starter price; $79/mo membership already inside the figure; shipping included.
$278/MO ALL-IN
RANK06
Found
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
THIRD-PARTY REPORTED · captured 2026-08-05 · source · archive
$289/MO ALL-IN
RANK08
LillyDirect (Zepbound)
No membership fee; shipping included; names its pharmacy network.
SOURCE-VERIFIED · captured 2026-08-09 · source
$449/MO ALL-IN
Not indexed anywhere on this site: "research use only" peptide vendors and gray-market sources — not legal for human use, not a lane, and responsible for a disproportionate share of the harm attributed to these medications online.
The leaders, across a full year
Stretch the leaders across twelve months and the ordering earns its meaning: NexLife: $2,580 monthly-billed, $2,232 on its prepaid path (upfront); Yucca Health↗: $3,096 monthly-billed; IVIM Health↗: $3,336 monthly-billed; Mochi Health↗: $3,336 monthly-billed; ShedRx: $3,468 monthly-billed; Found: $3,468 monthly-billed; LillyDirect (Zepbound): $5,388 monthly-billed.
Spread top-to-bottom within just these five: $2,808 a year — before considering the rest of the field, where the verified ceiling reaches $5,388. Prepaid paths shrink the totals and add commitment; the trade is priced properly in the annual-cost analysis and at your own numbers in the calculator.
Structure census across the 7 priced programs above: 4 are dose-flat, 5 carry no membership, 3 name their pharmacy network, and 1 publish a prepaid path below their own monthly-billed year. Those four counts are the shape of this list — the price column tells you what a program charges; the census tells you what kind of thing it is.
A ranking is a starting grid, not a finish line. The next click that earns its time: each shortlisted program’s provider page, where the same dataset renders the parts a single sorted number cannot carry — memberships, prepaid ladders, cancellation language, watch-outs, capture provenance.
Frequently asked
What is the cheapest option on this list?
NexLife at $215 per month all-in on the maintenance basis, captured 2026-08-10. Every figure here is medication plus mandatory fees; confirm at the provider's checkout before enrolling.
How is this ranking produced?
By sorting the public dataset on verified all-in monthly price at the maintenance dose — no editorial reordering, no paid placement. Basis, exclusions, and verification cycle: /methodology/; recompute it yourself from the JSON.
Are compounded GLP-1s on this page FDA-approved?
No compounded product is FDA-approved. Since 2025 compounded tirzepatide and semaglutide are limited to patient-specific 503A prescriptions with documented clinical need; brand options (Zepbound, Wegovy) are the approved products. Regulatory timeline: here.